Common use of EXPERTS Clause in Contracts

EXPERTS. The consolidated financial statements as of December 31, 2019 and 2018, and for the years then ended, incorporated by reference in this prospectus and the registration statement have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at xxx.xxx.xxx. Additional information about Heat Biologics, Inc. is contained at our website, xxx.xxxxxxxxxxxxx.xxx. Information on our website is not incorporated by reference into this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directors.

EXPERTS. The consolidated financial statements of ImmunityBio, Inc. appearing in ImmunityBio, Inc.’s Annual Report (Form 10-K) for the year ended December 31, 2021, and the effectiveness of ImmunityBio, Inc.’s internal control over financial reporting as of December 31, 2019 and 2018, and for the years then ended, incorporated by reference in this prospectus and the registration statement 2021 have been so incorporated in reliance on the report of BDO USA, audited by Xxxxx & Young LLP, an independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference, . Such consolidated financial statements are incorporated herein by reference in reliance upon such reports given on the authority of said such firm as experts in auditing accounting and accountingauditing. The report contains an explanatory paragraph regarding Because we are subject to the Company’s ability to continue as a going concern. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all information and reporting requirements of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectusExchange Act, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at xxx.xxx.xxxxxxxx://xxx.xxx.xxx. Additional In addition, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, including any amendments to those reports, and other information about Heat Biologics, Inc. is contained at our website, xxx.xxxxxxxxxxxxx.xxx. Information on that we file with or furnish to the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act can also be accessed free of charge through our website is not incorporated by reference into this prospectuslocated at xxxxx://xxx.xxxxxxxxxxx.xxx. We make These filings will be available on our website our SEC filings as soon as reasonably practicable after those reports we electronically file such material with, or furnish it to, the SEC. Information contained on or accessible through our website is not a part of this prospectus and is not incorporated by reference herein, and the inclusion of our website address and the SEC website address in this prospectus are inactive textual references only. Information contained on our website is not part of this prospectus. This prospectus and any accompanying prospectus supplement are part of a registration statement on Form S-3 that we have filed with the SEC and do not contain all the information we have included in the registration statement and the accompanying exhibits and schedules we have filed with the SEC. The following Corporate Governance Forms of the indenture and other documents establishing the terms of the offered securities are or may be filed as exhibits to the registration statement. Statements in this prospectus or any prospectus supplement about these documents are also posted on our website: Code of Ethics summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the registration statement, exhibits and schedules for a more complete description about us and the Charters for securities. The registration statement, exhibits and schedules are available through the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of DirectorsSEC’s Internet site.

EXPERTS. The consolidated financial statements of Data Storage Corporation as of December 31, 2019 2023 and 2018, 2022 and for each of the two years then endedin the period ended December 31, 2023 incorporated by reference in this prospectus and in the registration statement of which this prospectus forms a part have been so incorporated in reliance on the report of BDO USAXxxxxxxxx Xxxx Xxxxx Xxxxxx, LLPP.A., an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at xxx.xxx.xxx. Additional Our SEC filings are also available on our website,xxx.xxxx.xxx/xxx-xxxxxxx under the heading “SEC Filings.” The reference to our website is an inactive textual reference only, the information about Heat Biologicscontained in, Inc. is contained at and that can be accessed through our website, xxx.xxxxxxxxxxxxx.xxx. Information on our website is not incorporated by reference into and is not a part of this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directors.

EXPERTS. The consolidated financial statements as of December 31, 2019 and 2018, and for the years then ended, incorporated by reference in this prospectus and by reference from the registration statement Company’s Annual Report on Form 10-K have been so incorporated in reliance on the report of BDO USA, audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report, which is incorporated herein by reference, . Such financial statements have been so incorporated in reliance upon the report of such firm given on the upon their authority of said firm as experts in auditing accounting and accounting. The report contains an explanatory paragraph regarding the Company’s ability to continue as a going concernauditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter You should rely only on the information contained in this prospectus or dealer has incorporated by reference into this prospectus. We have not authorized any person anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our The SEC filings are available to the public at the SEC’s maintains a website at xxx.xxx.xxx. Additional that contains reports, proxy statements and other information about Heat Biologics, Inc. is contained at our website, xxx.xxxxxxxxxxxxx.xxx. Information on our website is not incorporated by reference into this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports are filed regarding issuers that file electronically with the SEC, including Fulgent. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee address of the Board SEC website is w xx.xxx.xxx. We maintain a website at w xx.xxxxxxxxxxxxxxx.xxx. Information contained in or accessible through our website does not constitute a part of Directorsthis prospectus.

EXPERTS. The consolidated financial statements of Amprius Technologies, Inc. as of and for the year ended December 31, 2019 and 2018, and for the years then ended, 2022 incorporated by reference in this prospectus Prospectus and in the registration statement Registration Statement have been so incorporated in reliance on the report of BDO USA, LLPLLP (n/k/a BDO USA, P.C.), an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The financial statements of Amprius Technologies, Inc. as of December 31, 2021 and for the year ended December 31, 2021 have been audited by XxxxxxXxxxx LLP, an independent registered public accounting firm, as stated in their report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement thereon and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in incorporated by reference into this prospectus is accurate in reliance upon such report and upon the authority of such firm as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectusexperts in accounting and auditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at xxx.xxx.xxx. Additional Copies of certain information about Heat Biologics, Inc. is contained filed by us with the SEC are also available on our website at our website, xxx.xxxxxxxxxxxxx.xxxxxxxxxx.xxx. Information accessible on or through our website is not incorporated by reference into a part of this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports are This prospectus and any prospectus supplement is part of a registration statement that we filed with the SECSEC and do not contain all of the information in the registration statement. The following Corporate Governance You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the securities that we are offering. Forms of any indenture or other documents establishing the terms of the offered securities are filed as exhibits to the registration statement of which this prospectus forms a part or under cover of a Current Report on Form 8-K and incorporated in this prospectus by reference. Statements in this prospectus or any prospectus supplement about these documents are also posted on our website: Code of Ethics summaries and each statement is qualified in all respects by reference to the Charters document to which it refers. You should read the actual documents for the Audit Committee, Compensation Committee and Nominating and Governance Committee a more complete description of the Board of Directorsrelevant matters.

EXPERTS. The consolidated financial statements of Zynerba Pharmaceuticals, Inc. and subsidiary as of December 31, 2020 and 2019 and 2018, and for each of the years then endedin the three-year period ended December 31, 2020, have been incorporated by reference in this prospectus and the registration statement have been so incorporated herein in reliance on upon the report of BDO USA, KPMG LLP, an independent registered public accounting firm, incorporated herein by referencereference herein, given on and upon the authority of said firm as experts in auditing accounting and accounting. The report contains an explanatory paragraph regarding the Company’s ability to continue as a going concernauditing. This prospectus supplement is part of a registration statement we filed with the SEC. This prospectus supplement does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectusprospectus supplement, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter You should rely only on the information contained in this prospectus supplement or dealer has incorporated by reference. We have not authorized any person anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date on the front page of this prospectusprospectus supplement, regardless of the time of delivery of this prospectus supplement or any sale of the securities offered by this prospectusprospectus supplement. We are currently subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and in accordance therewith file annual, quarterly and current periodic reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at you on the SEC’s website at xxx.xxx.xxx. Additional information about Heat Biologics, Inc. is contained at our website, xxx.xxxxxxxxxxxxx.xxx. Information on xxxx://xxx.xxx.xxx and in the “Investor Relations” section of our website is at xxxx://xxx.xxxxxxx.xxx. Our website and the information contained on that site, or connected to that site, are not incorporated by reference into and are not a part of this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directorsprospectus supplement.

EXPERTS. The consolidated financial statements as of December Sonoma Pharmaceuticals, Inc. appearing in Sonoma Pharmaceuticals, Inc.’s annual report on Form 10-K for the year ended March 31, 2019 and 20182020, and for the years then endedfiled on July 10, incorporated by reference in this prospectus and the registration statement 2020, have been so incorporated in reliance on the report of BDO USA, audited by Marcum LLP, an independent registered public accounting firm, as set forth in their report included therein, and incorporated herein by reference, . Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of said such firm as experts in auditing accounting and accounting. The report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectusauditing. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our You may read and copy the registration statement and any document we file with the SEC. The SEC filings are available to also maintains a web site that contains reports, proxy and information statements and other information regarding companies, such as ours, that file documents electronically with the public at SEC. The address of the SEC’s website at is xxx.xxx.xxx. Additional The information about Heat Biologics, Inc. is contained at our website, xxx.xxxxxxxxxxxxx.xxx. Information on our the SEC’s website is not part of this prospectus, and any references to this website or any other website are inactive textual references only. This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby. This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC’s website listed above. In addition to the foregoing, we maintain a website at xxx.xxxxxxxxxxxx.xxx. Our website content is made available for informational purposes only. It should neither be relied upon for investment purposes nor is it incorporated by reference into this prospectus. We make available at xxx.xxxxxxxxxxxx.xxx copies of our Annual Reports on our website our SEC filings Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any amendments to such document as soon as reasonably practicable after those reports are filed we electronically file such material with or furnish such documents to the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directors.

EXPERTS. The consolidated financial statements as of Bird Global, Inc., appearing in Bird Global, Inc.'s Annual Report (Form 10-K) for the year ended December 31, 2019 and 2018, and for the years then ended, incorporated by reference in this prospectus and the registration statement 2022 have been so incorporated in reliance on the report of BDO USA, audited by Xxxxx & Xxxxx LLP, an predecessor independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts set forth in auditing and accounting. The their report thereon (which contains an explanatory paragraph regarding describing conditions that raise substantial doubt about the Company’s 's ability to continue as a going concernconcern as described in Note 2 to the consolidated financial statements), included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such report given on the authority of such firm as experts in accounting and auditing. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agentYou should rely only on the information contained in this prospectus, underwriter or dealer has incorporated by reference in this prospectus. We have not authorized any person anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at xxx.xxx.xxxxxxx://xxx.xxx.xxx. Additional Copies of certain information about Heat Biologicsfiled by us with the SEC are also available on our website xxxxx.xxxx.xx. The information contained on, Inc. is contained at our websiteor accessible through, xxx.xxxxxxxxxxxxx.xxx. Information on our website is not incorporated by reference into this prospectus. We make available on , and you should not consider any information contained in, or that can be accessed through, our website as part of this prospectus, or in deciding whether to purchase our SEC filings as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directorssecurities.

EXPERTS. The consolidated financial statements as of December 31, 2019 and 2018, and for the years then ended, incorporated by reference in this prospectus supplement, the accompanying base prospectus and the registration statement have been so incorporated in reliance on the report of BDO USA, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. This prospectus supplement is part of a registration statement we filed with the SEC. This prospectus supplement does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus supplement and the accompanying base prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus supplement is accurate as of any date other than the date on the front page of this prospectusprospectus supplement, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectusprospectus supplement. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at xxx.xxx.xxx. Additional information about Heat Biologics, Inc. is contained at our website, xxx.xxxxxxxxxxxxx.xxx. Information on our website is not incorporated by reference into this prospectusprospectus supplement. We make available on our website our SEC filings as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directors.

EXPERTS. The consolidated financial statements of Xxxxx Life Sciences, Inc. as of December 31, 2019 and 2018, and for each of the years then endedin the three-year period ended December 31, 2019, have been incorporated by reference herein and in this prospectus and the registration statement have been so incorporated in reliance on upon the report of BDO USA, KPMG LLP, an independent registered public accounting firm, incorporated herein by referencereference herein, given on and upon the authority of said firm as experts in auditing accounting and accountingauditing. The audit report contains an explanatory paragraph regarding covering the Company’s ability December 31, 2019 consolidated financial statements refers to continue a change in the method of accounting for leases as a going concernof January 1, 2019 due to the adoption of FASB Accounting Standards Update 2016-02, Leases (Topic 842). This prospectus is part of a the registration statement on Form S-3 we filed with the SECSEC under the Securities Act. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter You should rely only on the information contained in this prospectus or dealer has incorporated by reference. We have not authorized any person anyone else to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to You may read and copy the public registration statement, as well as any other document filed by us with the SEC, at the SEC’s Public Reference Room at 000 X Xxxxxx XX, Xxxxxxxxxx, X.X. 00000. You can also request copies of these documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at (800) SEC-0330. The SEC maintains a website at xxx.xxx.xxx. Additional that contains reports, proxy and information about Heat Biologics, Inc. is contained at our website, xxx.xxxxxxxxxxxxx.xxx. Information on our website is not incorporated by reference into this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports are filed statements and other information regarding issuers that file electronically with the SEC, including Xxxxx. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee address of the Board SEC website is xxx.xxx.xxx. We maintain a website at xxx.xxxxxxxx.xxx. Information contained in or accessible through our website does not constitute a part of Directorsthis prospectus.

EXPERTS. The consolidated financial statements of Data Storage Corporation as of December 31, 2019 2023 and 2018, 2022 and for each of the two years then endedin the period ended December 31, 2023 incorporated by reference in this prospectus and in the registration statement of which this prospectus forms a part have been so incorporated in reliance on the report of BDO USAXxxxxxxxx Xxxx Xxxxx Xxxxxx, LLPP.A., an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern. This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC’s website at xxx.xxx.xxx. Additional Our SEC filings are also available on our website,xxx.xxxx.xxx under the heading “SEC Filings.” The reference to our website is an inactive textual reference only, the information about Heat Biologicscontained in, Inc. is contained at and that can be accessed through our website, xxx.xxxxxxxxxxxxx.xxx. Information on our website is not incorporated by reference into and is not a part of this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directors.

EXPERTS. The consolidated financial statements of Annexon, Inc. as of December 31, 2019 2023 and 20182022, and for each of the years then endedin the two-year period ended December 31, 2023, have been incorporated by reference herein and in this prospectus and the registration statement have been so incorporated in reliance on upon the report of BDO USA, KPMG LLP, an independent registered public accounting firm, incorporated herein by referencereference herein, given on and upon the authority of said such firm as experts in auditing accounting and accounting. The report contains an explanatory paragraph regarding the Company’s ability to continue as a going concernauditing. This prospectus is part of a the registration statement on Form S-3 we filed with the SEC. This prospectus SEC under the Securities Act and does not contain all of the information set forth in the registration statement statement. Whenever a reference is made in this prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits to the registration statement. For further information with respect to us and the securities we that are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statementstatement or the exhibits to the reports or other documents incorporated by reference into this prospectus for a copy of such contract, agreement or other document. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus. We Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the internet at the SEC’s website at xxx.xxx.xxxxxxx://xxx.xxx.xxx. Additional We maintain a website at xxx.xxxxxxxxxx.xxx. The information about Heat Biologicscontained in, Inc. is contained at our websiteor that can be accessed through, xxx.xxxxxxxxxxxxx.xxx. Information on our website is not incorporated by reference into part of this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directors.

EXPERTS. The consolidated financial statements of Nabriva Therapeutics plc as of December 31, 2019 and 2018, 2020 and for each of the years then endedin the three-year period ended December 31, 2020, have been incorporated by reference in this prospectus and the registration statement have been so incorporated herein in reliance on upon the report of BDO USA, KPMG LLP, an independent registered public accounting firm, incorporated herein by referencereference herein, given on and upon the authority of said firm as experts in auditing accounting and accountingauditing. The audit report covering the December 31, 2020 consolidated financial statements contains an explanatory paragraph regarding the Company’s that states that Xxxxxxx Therapeutics plc has incurred recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. This prospectus is part The consolidated financial statements do not include any adjustment that might result from the outcome of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different informationthat uncertainty. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that subject to the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless and periodic reporting requirements of the time Securities Exchange Act of delivery of this prospectus 1934, as amended, or any sale of the securities offered by this prospectus. We Exchange Act, and, in accordance therewith, file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at xxx.xxx.xxx. Additional Copies of certain information about Heat Biologics, Inc. is contained at our website, xxx.xxxxxxxxxxxxx.xxx. Information filed by us with the SEC are also available on our website at xxx.xxxxxxx.xxx. Our website is not a part of this prospectus supplement and is not incorporated by reference into in this prospectusprospectus supplement. We make available on our website our SEC filings as soon as reasonably practicable after those reports This prospectus supplement and the accompanying prospectus are part of a registration statement we filed with the SEC. The following Corporate Governance documents are also posted on our website: Code of Ethics This prospectus supplement and the Charters accompanying prospectus omit some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiaries and the Audit Committee, Compensation Committee securities we are offering. Statements in this prospectus supplement and Nominating the accompanying prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and Governance Committee of are qualified by reference to these filings. You should review the Board of Directorscomplete document to evaluate these statements.

EXPERTS. The consolidated financial statements as of incorporated in this prospectus by reference from our Annual Report on Form 10-K for the years ended December 31, 2019 2020 and 20182019, and for each of the years then endedin the period ended December 31, incorporated by reference in this prospectus and the registration statement 2020, have been so incorporated in reliance on the report of BDO USAXxxxxx, LLP, an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. The consolidated financial statements of Enertec Systems 2001 LTD., as of December 31, 2020 and December 31, 2019, and for the year ended December 31, 2020 incorporated by reference in this prospectus have been so incorporated in reliance on the report contains of BDO XXX XXXX, an explanatory paragraph regarding independent registered public accounting firm, incorporated herein by reference, given on the Company’s ability authority of said firm as experts in auditing and accounting. We have filed with the Commission a registration statement on Form S-3 under the Securities Act, with respect to continue as a going concernthe securities covered by this prospectus. This prospectus is and any prospectus supplement which form a part of a the registration statement we filed with the SEC. This prospectus statement, does not contain all of the information set forth in the registration statement and or the exhibits to the registration statementand schedules filed therewith. For further information with respect to us and the securities we are offering under covered by this prospectus, we refer you to please see the registration statement and the exhibits and schedules filed as a part of with the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities Any statements made in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale prospectus supplement concerning legal documents are not necessarily complete and you should read the documents that are filed as exhibits to the registration statement or otherwise filed with the Commission for a more complete understanding of the securities offered document or matter. A copy of the registration statement and the exhibits filed with the registration statement may be inspected without charge at the Public Reference Room maintained by this prospectusthe Commission, located at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. Please call the Commission at 1-800-SEC-0330 for more information about the operation of the Public Reference Room. The Commission also maintains an internet website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Commission. The address of the website is xxxx://xxx.xxx.xxx. We file annual, quarterly and current reports, proxy statements and other information with the SECCommission. You may read, without charge, and copy the documents we file at the Commission’s public reference room in Washington, D.C. at 000 X Xxxxxx, X.X., Xxxxxxxxxx, X.X. 00000. You can request copies of these documents by writing to the Commission and paying a fee for the copying cost. Please call the Commission at 1-800-SEC-0330 for further information on the public reference rooms. Our SEC filings with the Commission are available to the public at no cost from the SEC’s website at xxx.xxx.xxxxxxx://xxx.xxx.xxx. Additional The reports and other information about Heat Biologics, Inc. is contained filed by us with the Commission are also available at our website, xxx.xxxxxxxxxxxxx.xxxxxx.xxxxxxxxxx.xxx. Information contained on our website or that can be accessed through our website is not incorporated by reference into this prospectus. We make available on our website our SEC filings as soon as reasonably practicable after those reports are filed with the SEC. The following Corporate Governance documents are also posted on our website: Code prospectus or any prospectus supplement and should not be considered to be part of Ethics and the Charters for the Audit Committee, Compensation Committee and Nominating and Governance Committee of the Board of Directorsthis prospectus or any prospectus supplement.